

March 2020

## Inflammatory Markers in Bicuspid Transcatheter Aortic Valve Replacement

Molly N. Pantelic

Wayne State University School of Medicine, gg0023@wayne.edu

Paul Nona

Henry Ford Health System, PNONA1@hfhs.org

Dee Dee Wang

Henry Ford Health System, dwang2@hfhs.org

Follow this and additional works at: [https://digitalcommons.wayne.edu/som\\_srs](https://digitalcommons.wayne.edu/som_srs)

 Part of the [Cardiology Commons](#), and the [Cardiovascular Diseases Commons](#)

---

### Recommended Citation

Pantelic, Molly N.; Nona, Paul; and Wang, Dee Dee, "Inflammatory Markers in Bicuspid Transcatheter Aortic Valve Replacement" (2020). *Medical Student Research Symposium*. 46.  
[https://digitalcommons.wayne.edu/som\\_srs/46](https://digitalcommons.wayne.edu/som_srs/46)

This Research Abstract is brought to you for free and open access by the School of Medicine at DigitalCommons@WayneState. It has been accepted for inclusion in Medical Student Research Symposium by an authorized administrator of DigitalCommons@WayneState.

# **Inflammatory Markers in Bicuspid Transcatheter Aortic Valve Replacement**

Pantelic M.N., MS2, Nona P., MD, Wang D., MD.

## **Background**

Aortic stenosis (AS) has a prevalence of 2%. Valve replacement is the definitive treatment for AS, with transcatheter aortic valve replacement (TAVR) offering a minimally invasive alternative to surgery.

Bicuspid aortic valve (BAV) is the most common congenital cardiac abnormality. BAV patients are predisposed to AS, and comprise a distinct, younger TAVR patient population. Given limited prior work on inflammatory markers for TAVR risk assessment, this study sought to investigate if white blood cell count (WBC) correlates with BAV TAVR patient severity and post-TAVR outcomes.

## **Methods**

A single-center retrospective analysis was performed on patients with BAV who underwent TAVR from 2014 to 2018 (N=37). Patient demographics, symptomatic severity (NYHA class) and anatomic severity: aortic valve area (AVA) and indexed aortic valve area (AVAI) were collected. WBC prior to TAVR and post-TAVR complications/readmissions were also collected. Correlations between WBC, patient severity, and adverse outcomes were assessed using the Pearson and Spearman correlation tests, two-sample t-tests, and the Wilcoxon rank sum test.

## **Results**

A statistically significant correlation ( $p = .041$ ) was found between elevated pre-procedure WBC and patient NYHA class. No association was found between pre-procedure WBC and AVA ( $p = .723$ ), AVAI ( $p = .961$ ), or adverse outcomes/readmission post-procedure ( $p = .116$ ).

## **Conclusions**

A statistically significant correlation between pre-procedure WBC and NYHA class demonstrates that WBC is an accurate predictor of BAV patient's functional symptom severity and could thus serve as a readily-accessible metric to stratify BAV TAVR patients in pre-procedure planning. No correlation existed between WBC and anatomic valve severity.